東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Investing in Innovation: Evidence fr...

Stearns, Kira Ellen.

FindBook

Google Book

Amazon

博客來

Investing in Innovation: Evidence from the Pharmaceutical Industry.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Investing in Innovation: Evidence from the Pharmaceutical Industry./
作者:	Stearns, Kira Ellen.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2020,
面頁冊數:	209 p.
附註:	Source: Dissertations Abstracts International, Volume: 82-01, Section: B.
Contained By:	Dissertations Abstracts International82-01B.
標題:	Management. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28000635
ISBN:	9798635266298

Investing in Innovation: Evidence from the Pharmaceutical Industry.
Stearns, Kira Ellen.

Investing in Innovation: Evidence from the Pharmaceutical Industry. - Ann Arbor : ProQuest Dissertations & Theses, 2020 - 209 p.

Source: Dissertations Abstracts International, Volume: 82-01, Section: B.

Thesis (Ph.D.)--University of California, Los Angeles, 2020.

This item must not be sold to any third party vendors.

This dissertation explores the role that organizations play in bringing scientific innovations to society. Chapter 1 situates this work in the current landscape of innovation research and motivates the need for further research on this topic. Chapter 2 explores the role thatfailure, both technological and regulatory, plays in understanding how organizations make future investments in innovative projects. I find that following FDA rejection, biopharmaceutical firms become significantly less likely to further invest in unrelated products already under development. However, they experience a higher proportion of future successes, as they redirect investment into less risky innovations. In contrast, I find no evidence of these effects in response to technological failures at the end of clinical trials, suggesting that this effect is not driven by the loss of firm value nor does it support a traditional Bayesian updating framework. Rather, these findings are consistent with the idea that there is a difference between failure at the technological level versus failure at the decision making level.Chapter 3 illustrates how the boundaries of an organization influence the type of innovations in which organizations do and not choose to invest following a sudden reshuffling of consumer demand. I demonstrate that a sudden increase in market size (and therefore expected revenue) increases an established firm's propensity to make larger investments in products in their pipeline that are less likely to receive approval. However, I find that this result only holds for those organizations that diversify into fewer therapeutic spaces and are additionally more centralized. I theorize that, in line with findings from organizational economics and internal capital allocation inefficiency, this is due to management having greater control over resource allocation decisions in more centralized firms.Finally, Chapter 4 studies how the type of innovation pursued may affect market outcomes and competitive interactions between organizations. Using drug repurposing as a research context, I explore how the repurposing of a pharmaceutical drug for a new disease impacts its sales, and the sales of its competitors, for other approved uses. By leveraging variation in the combination of diseases that one drug treats and the timing of those disease approvals, I find a positive spillover effect of repurposing on sales of the drug for other diseases and this effect also spills over into the drug's close competitors. Furthermore, I find that this growth in sales comes at the expense of competitors further away in therapeutic type. These findings have important implications for a pharmaceutical firm's R&D strategy and the strategic responses to be made by competitors.

ISBN: 9798635266298Subjects--Topical Terms:

516664
Management.
Subjects--Index Terms:

Industrial organization

Investing in Innovation: Evidence from the Pharmaceutical Industry.
LDR:03986nmm a2200373 4500 001 2269465
005 20200908090520.5
008 220629s2020 ||||||||||||||||| ||eng d
020 $a 9798635266298
035 $a (MiAaPQ)AAI28000635
035 $a AAI28000635
040 $a MiAaPQ $c MiAaPQ
100 1 $a Stearns, Kira Ellen. $3 3546801
245 1 0 $a Investing in Innovation: Evidence from the Pharmaceutical Industry.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2020
300 $a 209 p.
500 $a Source: Dissertations Abstracts International, Volume: 82-01, Section: B.
500 $a Advisor: Lieberman, Marvin B.;Chen, Melvin Keith.
502 $a Thesis (Ph.D.)--University of California, Los Angeles, 2020.
506 $a This item must not be sold to any third party vendors.
520 $a This dissertation explores the role that organizations play in bringing scientific innovations to society. Chapter 1 situates this work in the current landscape of innovation research and motivates the need for further research on this topic. Chapter 2 explores the role thatfailure, both technological and regulatory, plays in understanding how organizations make future investments in innovative projects. I find that following FDA rejection, biopharmaceutical firms become significantly less likely to further invest in unrelated products already under development. However, they experience a higher proportion of future successes, as they redirect investment into less risky innovations. In contrast, I find no evidence of these effects in response to technological failures at the end of clinical trials, suggesting that this effect is not driven by the loss of firm value nor does it support a traditional Bayesian updating framework. Rather, these findings are consistent with the idea that there is a difference between failure at the technological level versus failure at the decision making level.Chapter 3 illustrates how the boundaries of an organization influence the type of innovations in which organizations do and not choose to invest following a sudden reshuffling of consumer demand. I demonstrate that a sudden increase in market size (and therefore expected revenue) increases an established firm's propensity to make larger investments in products in their pipeline that are less likely to receive approval. However, I find that this result only holds for those organizations that diversify into fewer therapeutic spaces and are additionally more centralized. I theorize that, in line with findings from organizational economics and internal capital allocation inefficiency, this is due to management having greater control over resource allocation decisions in more centralized firms.Finally, Chapter 4 studies how the type of innovation pursued may affect market outcomes and competitive interactions between organizations. Using drug repurposing as a research context, I explore how the repurposing of a pharmaceutical drug for a new disease impacts its sales, and the sales of its competitors, for other approved uses. By leveraging variation in the combination of diseases that one drug treats and the timing of those disease approvals, I find a positive spillover effect of repurposing on sales of the drug for other diseases and this effect also spills over into the drug's close competitors. Furthermore, I find that this growth in sales comes at the expense of competitors further away in therapeutic type. These findings have important implications for a pharmaceutical firm's R&D strategy and the strategic responses to be made by competitors.
590 $a School code: 0031.
650 4 $a Management. $3 516664
650 4 $a Operations research. $3 547123
650 4 $a Pharmaceutical sciences. $3 3173021
653 $a Industrial organization
653 $a Innovation
653 $a Pharmaceutical industry
653 $a Strategic management
653 $a Technology management
690 $a 0454
690 $a 0796
690 $a 0572
710 2 $a University of California, Los Angeles. $b Management (MS/PHD) 0535. $3 2093752
773 0 $t Dissertations Abstracts International $g 82-01B.
790 $a 0031
791 $a Ph.D.
792 $a 2020
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28000635